25 Mar 2020
EUR 750 million
|Date of agreement:||3 Dec 2013|
|Customer:||H. Lundbeck A/S|
|Amount in EUR:||EUR 75 million|
|NACE sector / loan type:||Manufacture of pharmaceuticals|
|Business area:||Industries and services|
The facility has been provided for research and development activities in the field of psychiatric disorders. The project involves R&D in three main biology platforms of the company’s product lines: synaptic transmission, neurodegeneration and neuroinflammation. These research areas entail several unmet medical needs in terms of curing or alleviating the symptoms of several mental disorders. The company is investing EUR 225 million within this area in 2013–2015.
Founded in 1915, H. Lundbeck A/S is a Denmark-based international pharmaceutical company which is engaged in the research, development, manufacturing and marketing of pharmaceuticals for the treatment of brain disorders, including Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. The company has a number of wholly owned subsidiaries, which are active in 57 countries. The company is listed on the NASDAQ OMX Copenhagen, though 70% of shares belong to the Lundbeck Foundation.
The project is expected to provide considerable support for the innovation of H. Lundbeck A/S. The company’s R&D investment programme can affect the innovation of other companies operating in the same industry or region through knowledge spill-overs. The social rate of return of this project is likely to exceed the private rate, because most of the R&D conducted by the company occurs within the member countries in collaboration with research institutes and companies. The project contributes to academic research in Denmark.
Research and development into pharmaceuticals is regarded as neutral from an environmental impact perspective.